Skip to main content

Effects of the probiotic Bifidobacterium animalis subsp. lactis on the non-surgical treatment of periodontitis. A histomorphometric, microtomographic and immunohistochemical study in rats

  • 2017-06-29
  • PLOS ONE 12(6)
    • M. S. Ricoldi
    • F. Furlaneto
    • L. Oliveira
    • G. C. Teixeira
    • Jéssica P Pischiotini
    • A. L. Moreira
    • E. Ervolino
    • M. N. de Oliveira
    • C. Bogsan
    • S. Salvador
    • M. Messora

Abstract

Lactobacillus probiotics have been investigated in periodontitis. However, the effects of the genus Bifidobacterium on periodontitis are hardly known. This study evaluated the effects of the probiotic (PROB) Bifidobacterium animalis subsp. lactis (B. lactis) HN019 as an adjunct to scaling and root planing (SRP) in rats with experimental periodontitis (EP). At baseline, 32 rats were assigned to 4 groups: C (control), PROB, EP-SRP and EP-SRP-PROB. In groups EP-SRP and EP-SRP-PROB, the mandibular first molars of the animals received a ligature. At day 14, the ligatures were removed and SRP was performed. Animals of groups PROB and EP-SRP-PROB were orally administered with 10 mL/day of 109 colony forming units of B. lactis HN019 for 15 days, starting at day 14. Animals were euthanized at day 29. Histomorphometric, microtomographic and immunohistochemical analyses were performed. Microbiological effects of B. lactis on biofilm were also evaluated. Data were statistically analyzed (ANOVA, Tukey; Kruskal-Wallis, Dunn's; Two-tailed t-test; p<0.05). Group EP-SRP-PROB presented reduced alveolar bone resorption and attachment loss when compared with Group EP-SRP (p<0.05). Group EP-SRP-PROB showed significantly fewer osteoclasts, increased expression of anti-inflammatory cytokines and reduced expression of proinflammatory cytokines compared with Group EP-SRP (p<0.05). B. lactis promoted a higher ratio between aerobic and anaerobic bacteria in biofilm samples (p<0.05). B. lactis HN019 may have a role in the treatment of EP in rats, as an adjunct to SRP.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactisImproved Aerobic to Anaerobic Bacteria RatioBeneficial
Moderate
Bifidobacterium animalis subsp. lactisIncreased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium animalis subsp. lactisReduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium animalis subsp. lactisReduced Attachment LossBeneficial
Moderate
Bifidobacterium animalis subsp. lactisReduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium animalis subsp. lactisReduced Proinflammatory Cytokine ExpressionBeneficial
Large
Bifidobacterium animalis subsp. lactis BS-01Altered Gut Microbiome CompositionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Increased Anti-Inflammatory Cytokine ExpressionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Reduced Attachment LossBeneficial
Moderate
Bifidobacterium animalis subsp. lactis BS-01Reduced Osteoclast ActivityBeneficial
Large
Bifidobacterium animalis subsp. lactis BS-01Reduced Pro-inflammatory Cytokine LevelsBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Improved Aerobic to Anaerobic Bacteria RatioBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Increased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium animalis subsp. lactis HN019Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Attachment LossBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Proinflammatory Cytokine ExpressionBeneficial
Large
Bifidobacterium animalis subsp. lactis LAFTI B94Increased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium animalis subsp. lactis LAFTI B94Increased Ratio of Aerobic to Anaerobic Bacteria in BiofilmBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced Attachment LossBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium animalis subsp. lactis LAFTI B94Reduced Pro-inflammatory Cytokine LevelsBeneficial
Moderate
Bifidobacterium lactis BS01Increased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium lactis BS01Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium lactis BS01Reduced Attachment LossBeneficial
Moderate
Bifidobacterium lactis BS01Reduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium lactis BS01Reduced Proinflammatory Cytokine ExpressionBeneficial
Large
Bifidobacterium lactis HN019Improved Aerobic to Anaerobic Bacteria RatioBeneficial
Moderate
Bifidobacterium lactis HN019Increased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium lactis HN019Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Attachment LossBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Proinflammatory Cytokine ExpressionBeneficial
Large
Bifidobacterium lactis MAK16B42LIncreased Anti-Inflammatory Cytokine LevelsBeneficial
Large
Bifidobacterium lactis MAK16B42LReduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Attachment LossBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Osteoclast NumberBeneficial
Moderate
Bifidobacterium lactis MAK16B42LReduced Proinflammatory Cytokine ExpressionBeneficial
Large
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.